SAB Biotherapeutics Statistics
Total Valuation
SABS has a market cap or net worth of $17.41 million. The enterprise value is $11.22 million.
Important Dates
The next estimated earnings date is Tuesday, June 10, 2025, after market close.
| Earnings Date | Jun 10, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
SABS has 9.29 million shares outstanding. The number of shares has increased by 41.12% in one year.
| Current Share Class | 9.29M |
| Shares Outstanding | 9.29M |
| Shares Change (YoY) | +41.12% |
| Shares Change (QoQ) | +0.00% |
| Owned by Insiders (%) | 20.27% |
| Owned by Institutions (%) | 13.93% |
| Float | 6.44M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 45.66 |
| Forward PS | 13.12 |
| PB Ratio | 0.81 |
| P/TBV Ratio | 0.81 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 29.68 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.69, with a Debt / Equity ratio of 0.32.
| Current Ratio | 1.69 |
| Quick Ratio | 1.33 |
| Debt / Equity | 0.32 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -135.73 |
Financial Efficiency
Return on equity (ROE) is -92.35% and return on invested capital (ROIC) is -61.14%.
| Return on Equity (ROE) | -92.35% |
| Return on Assets (ROA) | -48.28% |
| Return on Invested Capital (ROIC) | -61.14% |
| Return on Capital Employed (ROCE) | -148.57% |
| Revenue Per Employee | $5,997 |
| Profits Per Employee | -$544,069 |
| Employee Count | 63 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -29.55% in the last 52 weeks. The beta is 0.48, so SABS's price volatility has been lower than the market average.
| Beta (5Y) | 0.48 |
| 52-Week Price Change | -29.55% |
| 50-Day Moving Average | 1.59 |
| 200-Day Moving Average | 2.53 |
| Relative Strength Index (RSI) | 55.20 |
| Average Volume (20 Days) | 81,829 |
Short Selling Information
The latest short interest is 71,961, so 0.77% of the outstanding shares have been sold short.
| Short Interest | 71,961 |
| Short Previous Month | 99,928 |
| Short % of Shares Out | 0.77% |
| Short % of Float | 1.12% |
| Short Ratio (days to cover) | 1.32 |
Income Statement
In the last 12 months, SABS had revenue of $377,835 and -$34.28 million in losses. Loss per share was -$3.70.
| Revenue | 377,835 |
| Gross Profit | -29.39M |
| Operating Income | -42.29M |
| Pretax Income | -40.32M |
| Net Income | -34.28M |
| EBITDA | -38.71M |
| EBIT | -42.29M |
| Loss Per Share | -$3.70 |
Full Income StatementBalance Sheet
The company has $12.85 million in cash and $6.78 million in debt, giving a net cash position of $6.07 million or $0.65 per share.
| Cash & Cash Equivalents | 12.85M |
| Total Debt | 6.78M |
| Net Cash | 6.07M |
| Net Cash Per Share | $0.65 |
| Equity (Book Value) | 21.41M |
| Book Value Per Share | 2.30 |
| Working Capital | 6.64M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$31.34 million and capital expenditures -$208,188, giving a free cash flow of -$31.55 million.
| Operating Cash Flow | -31.34M |
| Capital Expenditures | -208,188 |
| Free Cash Flow | -31.55M |
| FCF Per Share | -$3.40 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -11,193.25% |
| Pretax Margin | -9,071.77% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SABS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -41.12% |
| Shareholder Yield | -41.12% |
| Earnings Yield | -198.33% |
| FCF Yield | -182.54% |
Analyst Forecast
The average price target for SABS is $11.17, which is 496.08% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $11.17 |
| Price Target Difference | 496.08% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 110.85% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on January 5, 2024. It was a reverse split with a ratio of 0.1:1.
| Last Split Date | Jan 5, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.1:1 |
Scores
SABS has an Altman Z-Score of -7.2 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -7.2 |
| Piotroski F-Score | 1 |